Unknown PHASE2 INTERVENTIONAL 1-arm NCT04792515

Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer (CCWSA/OAFLAG)

A Single-arm, Multicenter Clinical Study of Evaluating Camrelizumab Combined With SOX and/or Apatinib in the Treatment of Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Conditions Locally Advanced Gastric Cancer

Interventions Camrelizumab combined with SOX/ or apatinib

Updated 4 times since 2021 Last updated: Mar 9, 2021 Started: Jan 1, 2021 Primary completion: Jun 30, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Locally Advanced Gastric Cancer and is currently ongoing. First Affiliated Hospital Xi'an Jiaotong University leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Apr 2021 — Feb 2023 [monthly]

Recruiting PHASE2

First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Affiliated Hospital Xi'an Jiaotong University
Jiangsu HengRui Medicine Co., Ltd.

Data source: First Affiliated Hospital Xi'an Jiaotong University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xi'an, China